TENX vs. BASI, UBX, BIVI, IPA, COCP, BIOR, BCTX, JAN, APRE, and RNXT
Should you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Bioanalytical Systems (BASI), Unity Biotechnology (UBX), BioVie (BIVI), ImmunoPrecise Antibodies (IPA), Cocrystal Pharma (COCP), Biora Therapeutics (BIOR), BriaCell Therapeutics (BCTX), JanOne (JAN), Aprea Therapeutics (APRE), and RenovoRx (RNXT). These companies are all part of the "medical" sector.
Bioanalytical Systems (NASDAQ:BASI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Bioanalytical Systems has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.
Tenax Therapeutics has a consensus price target of $480.00, indicating a potential upside of 13,459.32%. Given Bioanalytical Systems' higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Bioanalytical Systems.
Tenax Therapeutics has a net margin of 0.00% compared to Tenax Therapeutics' net margin of -7.75%. Tenax Therapeutics' return on equity of -42.74% beat Bioanalytical Systems' return on equity.
In the previous week, Tenax Therapeutics' average media sentiment score of 0.00 equaled Bioanalytical Systems'average media sentiment score.
10.6% of Bioanalytical Systems shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 11.5% of Bioanalytical Systems shares are owned by insiders. Comparatively, 0.3% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Tenax Therapeutics received 12 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 58.58% of users gave Tenax Therapeutics an outperform vote while only 41.16% of users gave Bioanalytical Systems an outperform vote.
Bioanalytical Systems has higher revenue and earnings than Tenax Therapeutics.
Summary
Bioanalytical Systems and Tenax Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Tenax Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tenax Therapeutics Competitors List
Related Companies and Tools
